Bristol Myers Squibb (CELG-RI) Return on Capital Employed (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Return on Capital Employed of 6.84% for Q1 2026, up 479.0% YoY from 1.18% in Q1 2025, and down 4.01% sequentially from 6.58% in Q4 2025.
Bristol Myers Squibb (CELG-RI) Return on Capital Employed (2009 - 2026) Analysis & Trends
Bristol Myers Squibb has disclosed Return on Capital Employed across 17 years of filings, most recently posting 6.84% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 479.0% year-over-year to 6.84%; the TTM figure through Mar 2026 stood at 6.84% (up 479.0% YoY), while the FY2025 annual figure was 6.79%, up 2509.0% from the prior year.
- Return on Capital Employed eased to 6.84% in Q1 2026, from 6.58% in the prior quarter.
- Over the last five years, Return on Capital Employed for CELG-RI reached as high as 1.88% in Q1 2023 and fell as low as 32.22% in Q4 2024.
- The 5-year median for Return on Capital Employed is 6.58% (2025), against an average of 10.25%.
- Annual changes were most pronounced in 2024 — Return on Capital Employed sank 2904 bps — and 2025, when it surged 2564 bps.
- A 5-year view of Return on Capital Employed shows it stood at 3.21% in 2022, then grew by 1 bps to 3.18% in 2023, then tumbled by 915 bps to 32.22% in 2024, then soared by 80 bps to 6.58% in 2025, then retreated by 4 bps to 6.84% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 6.84%, 6.58%, and 9.78% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 42.94% |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 28.18% |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 16.47% |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 9.76% |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -5.22% |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 15.87% |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 21.53% |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | -10.20% |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Bristol Myers Squibb | 244.56 Mn | -10.21 Bn | 8.07 Bn | -6.84% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.84% |
| Dec 31, 2025 | -6.58% |
| Sep 30, 2025 | -9.78% |
| Jun 30, 2025 | -11.48% |
| Mar 31, 2025 | -11.63% |
| Dec 31, 2024 | -32.22% |
| Sep 30, 2024 | -26.26% |
| Jun 30, 2024 | -24.29% |
| Mar 31, 2024 | -23.72% |
| Dec 31, 2023 | -3.18% |
| Sep 30, 2023 | -2.78% |
| Jun 30, 2023 | -2.29% |
| Mar 31, 2023 | -1.88% |
| Dec 31, 2022 | -3.21% |
| Sep 30, 2022 | -2.72% |
| Jun 30, 2022 | -2.70% |
| Mar 31, 2022 | -2.78% |
| Dec 31, 2021 | -2.09% |
| Sep 30, 2021 | -16.45% |
| Jun 30, 2021 | -16.00% |